ArticleWorld journal of urology2025
Utility of restaging transurethral resection in patients with primary high-grade Ta bladder cancer.
Article in World journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeInternational guidelines present discrepancies concerning restaging transurethral resection (TURBT) for high-grade (HG) Ta bladder cancer. Recent studies with heterogeneous inclusion criteria have reported discordant results regarding its benefits. Our study aimed to assess the prognostic impact of restaging TURBT in patients with HG Ta that was fully resected during the initial TURBT.
methodsThis single-center retrospective study involved patients with HG Ta. Patients with a history of urothelial carcinoma ≥ HG Ta, macroscopically incomplete resection, or the absence of detrusor muscle in the resected tissue were excluded. The decision to perform restaging TURBT was left to the discretion of the operating surgeon. Adjuvant treatment and follow-up were conducted according to established guidelines.
resultsA total of 181 patients were identified, with 111 included in the survival analysis. Patients who underwent restaging TURBT presented more frequently with multifocal lesions and were more likely to receive adjuvant therapy. Conversely, patients who underwent only TURBT had a higher prevalence of previous low-grade Ta tumors. The median time to restaging TURBT was 49 days. Residual tumors were detected in 36.4%, with 4.6% classified as pT1. Restaging TURBT did not impact RFS. In multivariate analysis, the use of photodynamic diagnosis PDD (HR = 0.3, p = 0.03) and adjuvant therapy (HR = 0.5, p < 0.01) were associated with a reduced risk of recurrence. Restaging TURBT did not significantly influence PFS.
conclusionsRestaging TURBT did not affect the risk of recurrence or progression in patients with HG Ta following a complete initial TURBT. These findings are consistent with recent updates in clinical guidelines.
Indexed as
Identifiers
40551001What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.